Literature DB >> 31546518

Commentary: PACK-CXL in fungal keratitis.

Rashmi Deshmukh1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31546518      PMCID: PMC6786226          DOI: 10.4103/ijo.IJO_993_19

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
Corneal collagen crosslinking (CXL) was initially described as a treatment to stabilize progressive keratoconus.[1] It halts the progression of ectasia by inducing formation of covalent bonds among collagen fibers to prevent stromal weakening. This was the rationale behind studying the effects of CXL on corneal melts of noninfectious origin in 2000.[2] Iseli et al. then proceeded to evaluate the results of CXL in advanced infectious keratitis refractory to therapy and found that CXL was effective in these cases as well.[3] Furthermore, Makdoumi et al. conducted a study that demonstrated CXL to be effective in early microbial keratitis.[4] Since then, there have been multiple studies on the use of CXL in management of infective keratitis, and it has come to be known as photo-activated chromophore for infectious keratitis (PACK)-CXL. The antimicrobial effect of CXL is due to the interaction between the ultraviolet-A (UV-A) radiation with the riboflavin acting as a chromophore. UV-A radiation itself is known to have antimicrobial properties and damages both RNA and DNA. This property is made use of when UV-A is used for disinfecting water and air. In addition, the reactive oxygen species generated during the photochemical reaction result in new covalent bonds and improve the resistance of corneal stroma against enzymatic degradation.[5] Most of the studies till date have used the standard Dresden protocol with UV-A radiation exposure of 3 mW/cm2 for 30 min.[6] However, reports exist about the successful use of accelerated protocol using 9 mW/cm2 for 10 min.[7] The effects of PACK-CXL have been studied on various etiologies of infective keratitis. In 2013, a meta-analysis by Alio et al. reported that the effectiveness of CXL to reduce the corneal melt was in the following order from most to least: Gram-negative bacteria, Gram-positive bacteria, Acanthamoeba, and fungus.[6] The poor response in fungal infections may be explained by the fact that fungal infections penetrate deeper and CXL is known to have effect in the anterior two-third of the corneal stroma. Tabibian et al. used PACK-CXL as a first line of treatment and found that early fungal keratitis being superficial responded well to CXL alone. The fungus isolated was Aureobasidium pullulans.[7] Vajpayee et al. conducted a retrospective study on moderate grade mycotic keratitis and found that in these cases, addition of CXL to medical treatment did not affect the final outcome. Aspergillus was the most common fungus to be isolated in their study.[8] In advanced and deep stromal fungal ulcers, CXL has been shown to be ineffective.[9] It has been reported that use of 0.25% riboflavin has a higher fungicidal effect than 0.1% riboflavin.[10]Özdemir et al. used 0.25% riboflavin and accelerated CXL protocol and showed that CXL was effective in Fusarium and Candida keratitis as well. The effect was better when PACK-CXL was combined with medical treatment.[11] The case reported by Thakur et al.[12] shows successful resolution of a corneal fungal infiltrate at the site of phaco-tunnel. They used 0.1% riboflavin with Dresden protocol. Although the organism was not isolated, the aqueous tap was positive for fungal genome. It is possible that PACK-CXL had a synergistic effect with the already administered antifungal medical treatment. The case highlights that CXL was effective in deep fungal infiltrate when used as an adjuvant treatment. Since there are prior studies to show that deep fungal infiltrates have a poor response to CXL, it is difficult to comment whether this infection would have responded to PACK-CXL alone [Table 1]. Nevertheless, further studies on the effects of CXL on fungal keratitis are needed to understand whether deep stromal infiltrates are likely to respond well.
Table 1

Studies on PACK-CXL in fungal keratitis

AuthorsYearNumber of eyes with fungal keratitisFungusOutcome
Iseli et al.[3]20082Acremonium and FusariumResolution of infection with scarring
Vajpayee et al.[8]201520Aspergillus, FusariumPACK-CXL did not have additional benefit over medical treatment in moderate mycotic keratitis
Erdem et al.[13]201713Aspergillus, FusariumPACK-CXL was effective in early and superficial infections, but ineffective in deep stromal infiltrates
Basaiawmoit et al.[14]20184Aspergillus, unidentified septate hyphaePACK-CXL reduced healing time in ulcers less than 6 mm in diameter

PACK: Photo-activated chromophore for infectious keratitis; CXL: Crosslinking

Studies on PACK-CXL in fungal keratitis PACK: Photo-activated chromophore for infectious keratitis; CXL: Crosslinking
  14 in total

1.  Accelerated photoactivated chromophore for keratitis-corneal collagen cross-linking as a first-line and sole treatment in early fungal keratitis.

Authors:  David Tabibian; Olivier Richoz; Arnaud Riat; Jacques Schrenzel; Farhad Hafezi
Journal:  J Refract Surg       Date:  2014-12       Impact factor: 3.573

2.  PACK-CXL in Reducing the Time to Heal in Suppurative Corneal Ulcers: Observations of a Pilot Study From South India.

Authors:  Priya Basaiawmoit; Satheesh Solomon T Selvin; Sanita Korah
Journal:  Cornea       Date:  2018-11       Impact factor: 2.651

3.  UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study.

Authors:  Karim Makdoumi; Jes Mortensen; Omid Sorkhabi; Bo-Eric Malmvall; Sven Crafoord
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-27       Impact factor: 3.117

4.  Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus.

Authors:  Gregor Wollensak; Eberhard Spoerl; Theo Seiler
Journal:  Am J Ophthalmol       Date:  2003-05       Impact factor: 5.258

5.  Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts.

Authors:  Hans Peter Iseli; Michael A Thiel; Farhad Hafezi; Juergen Kampmeier; Theo Seiler
Journal:  Cornea       Date:  2008-06       Impact factor: 2.651

6.  Evaluation of Antifungal Efficacy of 0.1% and 0.25% Riboflavin with UVA: A Comparative In Vitro Study.

Authors:  Kamil Bilgihan; Ayse Kalkanci; Huseyin Baran Ozdemir; Reyhan Yazar; Funda Karakurt; Erdem Yuksel; Feza Otag; Nilgun Karabicak; Sevtap Arikan-Akdagli
Journal:  Curr Eye Res       Date:  2015-12-07       Impact factor: 2.424

7.  Corneal Collagen Cross-Linking for the Management of Mycotic Keratitis.

Authors:  Elif Erdem; Ibrahim Inan Harbiyeli; Hazal Boral; Macit Ilkit; Meltem Yagmur; Reha Ersoz
Journal:  Mycopathologia       Date:  2018-02-16       Impact factor: 2.574

8.  Comparison of corneal collagen cross-linking (PACK-CXL) and voriconazole treatments in experimental fungal keratitis.

Authors:  Hüseyin Baran Özdemir; Ayşe Kalkancı; Kamil Bilgihan; Pınar Uyar Göçün; Betül Öğüt; Funda Karakurt; Merve Erdoğan
Journal:  Acta Ophthalmol       Date:  2018-06-04       Impact factor: 3.761

9.  Evaluation of corneal collagen cross-linking as an additional therapy in mycotic keratitis.

Authors:  Rasik B Vajpayee; Shah N Shafi; Prafulla K Maharana; Namrata Sharma; Vishal Jhanji
Journal:  Clin Exp Ophthalmol       Date:  2014-09-27       Impact factor: 4.207

10.  Corneal cross linking and infectious keratitis: a systematic review with a meta-analysis of reported cases.

Authors:  Jorge L Alio; Alessandro Abbouda; David Diaz Valle; Jose M Benitez Del Castillo; Jose A Gegundez Fernandez
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.